Michael Martin Breen - 27 Jan 2023 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Role
Exec Chairman and Interim CEO, Director
Signature
/s/ Michael Martin Breen
Issuer symbol
GTBP
Transactions as of
27 Jan 2023
Net transactions value
$0
Form type
4
Filing time
01 Feb 2023, 05:05:38 UTC
Previous filing
19 Jul 2022
Next filing
11 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTBP Option to purchase Common Stock Award $0 +500,000 $0.000000 500,000 27 Jan 2023 Common Stock 500,000 $0.8370 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct, and the reporting person is involuntarily terminated by the registrant.